Harmony Biosciences (HRMY) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Harmony Biosciences (HRMY) over the past year, gaining 483.4% versus a gain of 49.1%. Over five years, SLS leads with a +27.5% price change compared with +0.5% for HRMY. SELLAS Life Sciences Group is the larger company by market cap ($2.35 billion vs $2.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | SLS |
|---|---|---|
| Share price | $40.28 | $11.65 |
| Market cap | $2.35B | $2.35B |
| 1-day change | +1.72% | +3.46% |
| YTD return | +5.83% | +198.67% |
| 1-year return | +49.10% | +483.42% |
| 5-year return | +0.51% | +27.52% |
| P/E ratio (TTM) | 12.99 | — |
| Forward P/E | 5.75 | — |
| EPS (TTM) | $3.10 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | — |
| Revenue growth (YoY) | +21.51% | — |
| Net income (latest FY) | $158.69M | $-26.86M |
| Gross margin | 77.16% | — |
| Operating margin | 24.00% | — |
| Net margin | 18.27% | — |
| 52-week high | $43.49 | $15.88 |
| 52-week low | $25.52 | $1.39 |
| Distance from 52-week high | -7.38% | -26.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +18.27% | +178.97% |
| Average volume | 892.55K | 6.52M |
| Shares outstanding | 58.24M | 201.95M |
| Employees | 293 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed HRMY by 434.3 percentage points over the past year.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
HRMY vs SLS FAQ
Which is bigger, Harmony Biosciences or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.35B compared with $2.35B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, HRMY or SLS?
SLS returned +483.42% over the past 12 months, compared with +49.10% for HRMY (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.